Endometrial cancer-is our knowledge changing?

Area of Science:

• Gynecologic Oncology
• Cancer Research

Background:

• Endometrial cancer (EC) is a leading gynecologic malignancy in postmenopausal women, with increasing incidence in developing nations linked to obesity.
• While low-grade EC has a good prognosis, high-risk EC survival rates remain poor, indicating a need for improved strategies.
• Current standard treatments (surgery, radiation, chemotherapy) have limitations and side effects, and molecular findings have yet to translate effectively into clinical practice.

Purpose of the Study:

• To review recent advancements in identifying biomarkers and prognostic markers for endometrial cancer.
• To discuss progress and challenges in the treatment of endometrial cancer.
• To provide an overview of the current landscape of endometrial cancer research and clinical management.

Main Methods:

• Literature review of recent studies on endometrial cancer biomarkers.
• Analysis of current treatment modalities and their efficacy.
• Synthesis of research findings on risk factors, diagnosis, and molecular mechanisms.

Main Results:

• Ongoing research is exploring novel biomarkers and prognostic indicators for endometrial cancer.
• Despite molecular understanding, translation into improved diagnosis and therapy for EC is limited.
• Standard EC treatments persist, highlighting the need for more targeted and effective therapeutic approaches.

Conclusions:

• Further research is crucial to translate molecular discoveries into clinical applications for endometrial cancer.
• Development of new biomarkers and targeted therapies is essential to improve outcomes for high-risk EC patients.
• A comprehensive approach integrating biomarker discovery and treatment innovation is needed to combat endometrial cancer effectively.